Moderna (MRNA)
(Delayed Data from NSDQ)
$57.31 USD
-0.42 (-0.73%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $57.29 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.31 USD
-0.42 (-0.73%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $57.29 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Zacks News
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
Stock Market News for May 19, 2020
by Zacks Equity Research
Wall Street rebounded impressively on Monday buoyed by an encouraging early-stage clinical trial data for a potential coronavirus vaccine.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Major Indexes Defying "Sell in May" Adage: 5 Growth Picks
by Nalak Das
Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."
Here's Why Moderna (MRNA) Stock is Jumping Today
by Madeleine Johnson
On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.
Buy Nvidia & Alibaba Stock Before Earnings for Coronavirus Resilience?
by Benjamin Rains
We dive into Nvidia and Alibaba ahead of their quarterly earnings results that are due out this week to help investors decide if either stock might worth buying...
Moderna Soars: Biotech ETFs in Focus
by Neena Mishra
Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.
Market Gains on Powell's Speech and Moderna's Vaccine
by Zacks Equity Research
Market Gains on Powell's Speech and Moderna's Vaccine.
Moderna (MRNA) COVID-19 Vaccine Looks Promising
by Mark Vickery
This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Traders Focus on Powell's Comments
by Jeremy Mullin
Futures are flying high before the bell.
Stocks Take a Breather, but Good Weekend News Promises a Boost
by David Borun
Positive comments from the Fed Chairman and promising vaccine trial results provide a chance for a meaningful rally.
Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis
by Neena Mishra
The pandemic will forever transform our lives; here are some areas that may benefit.
The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills
Rebalance Your Portfolio to Counter Dilemma Over Recovery
by Nalak Das
At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.
Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine
by Zacks Equity Research
Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
6 Leveraged ETFs Up At Least 25% Last Week
by Sanghamitra Saha
Oil, tech and biotech caused a rally in the leveraged ETF space last week.
An Outstanding Week for Market Amid Record Job Losses: 5 Picks
by Nalak Das
Market's worst is behind us as negative estimates are already factored in valuations.
6 ETF Areas Beating S&P 500 in 2020
by Sanghamitra Saha
The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.
Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 5.41% and -53.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?